Withdrawal Of Atrioventricular Nodal Blocking Agents in Patients Receiving Mavacamten: A Retrospective Single-Center Experience in A Predominantly Asian-American Cohort
Hypertrophic obstructive cardiomyopathy (HOCM) is a hereditary condition in which cardiac muscle progressively hypertrophies, leading to hypercontractility, impaired relaxation, and blockage of the left ventricular outflow tract (LVOT).1 Mavacamten is a recently approved medication that inhibits myosin activation, improving quality of life, functional status, and cardiac function.2 –6
Source: The American Journal of Cardiology - Category: Cardiology Authors: Kevin Benavente, Jesus Pino Moreno, Dipanjan Banerjee Tags: Brief Report Source Type: research